High-content assay to identify inhibitors of dengue virus infection

David Shum, Jessica L. Smith, Alec Hirsch, Bhavneet Bhinder, Constantin Radu, David A. Stein, Jay Nelson, Klaus Frueh, Hakim Djaballah

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Dengue virus (DENV) infections are vectored by mosquitoes and constitute one of the most prevalent infectious diseases in many parts of the world, affecting millions of people annually. Current treatments for DENV infections are nonspecific and largely ineffective. In this study, we describe the adaptation of a high-content cell-based assay for screening against DENV-infected cells to identify inhibitors and modulators of DENV infection. Using this high-content approach, we monitored the inhibition of test compounds on DENV protein production by means of immunofluorescence staining of DENV glycoprotein envelope, simultaneously evaluating cytotoxicity in HEK293 cells. The adapted 384-well microtiter-based assay was validated using a small panel of compounds previously reported as having inhibitory activity against DENV infections of cell cultures, including compounds with antiviral activity (ribavirin), inhibitors of cellular signaling pathways (U0126), and polysaccharides that are presumed to interfere with virus attachment (carrageenan). A screen was performed against a collection of 5,632 well-characterized bioactives, including U.S. Food and Drug Administration- approved drugs. Assay control statistics show an average Z' of 0.63, indicative of a robust assay in this cell-based format. Using a threshold of >80% DENV inhibition with 50 potencies ranging from 60nM to 9μM and yielding a hit rate of 1.3%. Over half of the confirmed hits are known to target transporters, receptors, and protein kinases, providing potential opportunity for drug repurposing to treat DENV infections. In summary, this assay offers the opportunity to screen libraries of chemical compounds, in an effort to identify and develop novel drug candidates against DENV infections.

Original languageEnglish (US)
Pages (from-to)553-570
Number of pages18
JournalAssay and Drug Development Technologies
Volume8
Issue number5
DOIs
StatePublished - Oct 1 2010

Fingerprint

Dengue Virus
Virus Diseases
Drug Repositioning
Small Molecule Libraries
Virus Attachment
Ribavirin
HEK293 Cells
Carrageenan
United States Food and Drug Administration
Culicidae
Pharmaceutical Preparations
Protein Kinases
Antiviral Agents
Fluorescent Antibody Technique
Communicable Diseases
Polysaccharides
Glycoproteins
Cell Culture Techniques
Staining and Labeling

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Shum, D., Smith, J. L., Hirsch, A., Bhinder, B., Radu, C., Stein, D. A., ... Djaballah, H. (2010). High-content assay to identify inhibitors of dengue virus infection. Assay and Drug Development Technologies, 8(5), 553-570. https://doi.org/10.1089/adt.2010.0321

High-content assay to identify inhibitors of dengue virus infection. / Shum, David; Smith, Jessica L.; Hirsch, Alec; Bhinder, Bhavneet; Radu, Constantin; Stein, David A.; Nelson, Jay; Frueh, Klaus; Djaballah, Hakim.

In: Assay and Drug Development Technologies, Vol. 8, No. 5, 01.10.2010, p. 553-570.

Research output: Contribution to journalArticle

Shum, David ; Smith, Jessica L. ; Hirsch, Alec ; Bhinder, Bhavneet ; Radu, Constantin ; Stein, David A. ; Nelson, Jay ; Frueh, Klaus ; Djaballah, Hakim. / High-content assay to identify inhibitors of dengue virus infection. In: Assay and Drug Development Technologies. 2010 ; Vol. 8, No. 5. pp. 553-570.
@article{86932882cd2441d5950ab0411f084412,
title = "High-content assay to identify inhibitors of dengue virus infection",
abstract = "Dengue virus (DENV) infections are vectored by mosquitoes and constitute one of the most prevalent infectious diseases in many parts of the world, affecting millions of people annually. Current treatments for DENV infections are nonspecific and largely ineffective. In this study, we describe the adaptation of a high-content cell-based assay for screening against DENV-infected cells to identify inhibitors and modulators of DENV infection. Using this high-content approach, we monitored the inhibition of test compounds on DENV protein production by means of immunofluorescence staining of DENV glycoprotein envelope, simultaneously evaluating cytotoxicity in HEK293 cells. The adapted 384-well microtiter-based assay was validated using a small panel of compounds previously reported as having inhibitory activity against DENV infections of cell cultures, including compounds with antiviral activity (ribavirin), inhibitors of cellular signaling pathways (U0126), and polysaccharides that are presumed to interfere with virus attachment (carrageenan). A screen was performed against a collection of 5,632 well-characterized bioactives, including U.S. Food and Drug Administration- approved drugs. Assay control statistics show an average Z' of 0.63, indicative of a robust assay in this cell-based format. Using a threshold of >80{\%} DENV inhibition with 50 potencies ranging from 60nM to 9μM and yielding a hit rate of 1.3{\%}. Over half of the confirmed hits are known to target transporters, receptors, and protein kinases, providing potential opportunity for drug repurposing to treat DENV infections. In summary, this assay offers the opportunity to screen libraries of chemical compounds, in an effort to identify and develop novel drug candidates against DENV infections.",
author = "David Shum and Smith, {Jessica L.} and Alec Hirsch and Bhavneet Bhinder and Constantin Radu and Stein, {David A.} and Jay Nelson and Klaus Frueh and Hakim Djaballah",
year = "2010",
month = "10",
day = "1",
doi = "10.1089/adt.2010.0321",
language = "English (US)",
volume = "8",
pages = "553--570",
journal = "Assay and Drug Development Technologies",
issn = "1540-658X",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - High-content assay to identify inhibitors of dengue virus infection

AU - Shum, David

AU - Smith, Jessica L.

AU - Hirsch, Alec

AU - Bhinder, Bhavneet

AU - Radu, Constantin

AU - Stein, David A.

AU - Nelson, Jay

AU - Frueh, Klaus

AU - Djaballah, Hakim

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Dengue virus (DENV) infections are vectored by mosquitoes and constitute one of the most prevalent infectious diseases in many parts of the world, affecting millions of people annually. Current treatments for DENV infections are nonspecific and largely ineffective. In this study, we describe the adaptation of a high-content cell-based assay for screening against DENV-infected cells to identify inhibitors and modulators of DENV infection. Using this high-content approach, we monitored the inhibition of test compounds on DENV protein production by means of immunofluorescence staining of DENV glycoprotein envelope, simultaneously evaluating cytotoxicity in HEK293 cells. The adapted 384-well microtiter-based assay was validated using a small panel of compounds previously reported as having inhibitory activity against DENV infections of cell cultures, including compounds with antiviral activity (ribavirin), inhibitors of cellular signaling pathways (U0126), and polysaccharides that are presumed to interfere with virus attachment (carrageenan). A screen was performed against a collection of 5,632 well-characterized bioactives, including U.S. Food and Drug Administration- approved drugs. Assay control statistics show an average Z' of 0.63, indicative of a robust assay in this cell-based format. Using a threshold of >80% DENV inhibition with 50 potencies ranging from 60nM to 9μM and yielding a hit rate of 1.3%. Over half of the confirmed hits are known to target transporters, receptors, and protein kinases, providing potential opportunity for drug repurposing to treat DENV infections. In summary, this assay offers the opportunity to screen libraries of chemical compounds, in an effort to identify and develop novel drug candidates against DENV infections.

AB - Dengue virus (DENV) infections are vectored by mosquitoes and constitute one of the most prevalent infectious diseases in many parts of the world, affecting millions of people annually. Current treatments for DENV infections are nonspecific and largely ineffective. In this study, we describe the adaptation of a high-content cell-based assay for screening against DENV-infected cells to identify inhibitors and modulators of DENV infection. Using this high-content approach, we monitored the inhibition of test compounds on DENV protein production by means of immunofluorescence staining of DENV glycoprotein envelope, simultaneously evaluating cytotoxicity in HEK293 cells. The adapted 384-well microtiter-based assay was validated using a small panel of compounds previously reported as having inhibitory activity against DENV infections of cell cultures, including compounds with antiviral activity (ribavirin), inhibitors of cellular signaling pathways (U0126), and polysaccharides that are presumed to interfere with virus attachment (carrageenan). A screen was performed against a collection of 5,632 well-characterized bioactives, including U.S. Food and Drug Administration- approved drugs. Assay control statistics show an average Z' of 0.63, indicative of a robust assay in this cell-based format. Using a threshold of >80% DENV inhibition with 50 potencies ranging from 60nM to 9μM and yielding a hit rate of 1.3%. Over half of the confirmed hits are known to target transporters, receptors, and protein kinases, providing potential opportunity for drug repurposing to treat DENV infections. In summary, this assay offers the opportunity to screen libraries of chemical compounds, in an effort to identify and develop novel drug candidates against DENV infections.

UR - http://www.scopus.com/inward/record.url?scp=77958613347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958613347&partnerID=8YFLogxK

U2 - 10.1089/adt.2010.0321

DO - 10.1089/adt.2010.0321

M3 - Article

C2 - 20973722

AN - SCOPUS:77958613347

VL - 8

SP - 553

EP - 570

JO - Assay and Drug Development Technologies

JF - Assay and Drug Development Technologies

SN - 1540-658X

IS - 5

ER -